Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

Clinical trial NCT02492711 · COMPLETED

Trial details

NCT number: NCT02492711
Sponsor: MacroGenics
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HER-2 Positive Breast Cancer Metastatic Neoplasm

Start date: 2015-08-24
Primary completion: 2021-08-11
Enrollment: 624

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.